Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorJinling Hospital, China
About this trial
To conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.
Eligibility criteria
Qualifiers
Newly diagnosed renal cell carcinoma
Without any treatment
Agree and accept radical surgical treatment
Signed written informed consent
Disqualifiers
Had other cancers
Had received any antitumor therapy before
Known or suspected active autoimmune disease
Informed consent is not possible due to medical or psychiatric problems
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China210000, NanjingJiangsu, China
Sponsors and collaborators
Jinling Hospital, China
Lead sponsor
Source ClinicalTrials.gov